Spinraza rivals and Tecfidera patent challenges were in the spotlight as $BIIB provided few details about its planned filing for aducanumab.https://www.biopharmadive.com/news/biogen-earnings-aducanumab-tecfidera-spinraza/571413/ …
U tweetove putem weba ili aplikacija drugih proizvođača možete dodati podatke o lokaciji, kao što su grad ili točna lokacija. Povijest lokacija tweetova uvijek možete izbrisati. Saznajte više
Spinraza rivals and Tecfidera patent challenges were in the spotlight as $BIIB provided few details about its planned filing for aducanumab.https://www.biopharmadive.com/news/biogen-earnings-aducanumab-tecfidera-spinraza/571413/ …